Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 9/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | CASP7 | P55210 | 1/20 | 0.48 |
| ▸ | CASP9 | P55211 | 1/20 | 0.48 |
| ▸ | TGM2 | P21980 | 5/20 | 0.45 |
| ▸ | CES1 | P23141 | 3/20 | 0.43 |
| ▸ | MAOA | P21397 | 3/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | CAPN9 | O14815 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1091461 | 0.79 | CA12 (0.55) | CA12CA1CA2CA9TSHR | |
| SCHEMBL14111818 | 0.78 | CASP3 (0.54) | CA12CA1CA2CA9TSHR | |
| SCHEMBL1092244 | 0.77 | MGAT2 (0.65) | CA12CA1CA2CA9MAOA | |
| SCHEMBL5894519 | 0.76 | CA12 (0.63) | CA12CA1CA2CA9CASP3 | |
| SCHEMBL14111831 | 0.76 | ALDH1A1 (0.67) | CA12CA1CA2CA9TSHR | |
| SCHEMBL564534 | 0.75 | MAOB (0.60) | CA12CA1CA2CA9CASP3 | |
| SCHEMBL4906816 | 0.75 | MAOA (0.60) | TSHRMAPK1MAOAMAOB | |
| SCHEMBL4411616 | 0.75 | POLB (0.62) | CA12CA1CA2CA9MAPK1 | |
| SCHEMBL14111824 | 0.75 | SMN1; SMN2 (0.57) | CA12CA1CA2CA9TSHR | |
| SCHEMBL14111817 | 0.73 | ALDH1A1 (0.52) | CA12CA1CA2CA9MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1087663-A4 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORP (US) | 2004-09-08 | — | — | EP | disclosed |
| EP-1242081-A4 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORP (US) | 2004-07-21 | — | — | EP | disclosed |
| US-6514992-B1 | Excessive or inappropriate apoptosis in the neuronal cells occurs in Alzheimer disease and ischemia, T cells in HIV and cardiac myocytes during infarction/reperfusion; caspases inhibit apoptosis | SMITHKLINE BEECHAM CORPORATION | 2003-02-04 | — | — | US | disclosed |
| EP-1001933-A4 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORP (US) | 2002-11-06 | — | — | EP | disclosed |
| EP-1242081-A1 | CASPASES AND APOPTOSIS | SmithKline Beecham Corporation (US) | 2002-09-25 | — | — | EP | disclosed |
| US-6403792-B1 | INHIBIT PRODUCTION OF CASPASE 3 AND 7 IN MAMMALS | SMITHKLINE BEECHAM CORPORATION | 2002-06-11 | — | — | US | disclosed |
| WO-2001022966-A1 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-04-05 | — | — | WO | disclosed |
| EP-1087663-A2 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-04-04 | — | — | EP | disclosed |
| EP-1001933-A1 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999065451-A2 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-12-23 | — | — | WO | disclosed |
| WO-1999006367-A1 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-02-11 | — | — | WO | disclosed |